Healios is a Japanese company committed to advancing the possibilities of humanity through the power of the bio-revolution, which is the most groundbreaking technological innovation humanity has ever achieved. They leverage Japan's pride, iPSC regenerative medicine, and use it to bring healing to patients suffering from various diseases worldwide. Healios is focused on the field of regenerative medicine, specifically iPSC regenerative medicine.

Their pipeline includes a wide range of therapeutic areas such as universal donor cells, cancer immunotherapy (NK cells), age-related macular degeneration, liver diseases, stem cell-based regenerative medicine, stroke, and acute respiratory distress syndrome (ARDS). They are dedicated to developing effective treatments for these challenging conditions by harnessing the potential of iPSC technology. Healios's mission is driven by the heartfelt desire to answer the question asked by a patient: Can my eye disease be cured? This question inspired the founder, and the company is dedicated to developing effective therapies to bring hope and healing to patients in need.

With their extensive expertise and collaborations, Healios aims to realize their vision of delivering innovative treatments in the field of regenerative medicine